早产儿视网膜病变低剂量贝伐珠单抗治疗后血浆贝伐珠单抗与血管内皮生长因子水平
这项1期剂量递减病例系列研究在美国10家医院纳入83例1型早产儿视网膜病变患儿,眼内注射0.250 mg至0.002 mg贝伐珠单抗后2周和4周采血。基线总剂量越高,2周和4周血浆贝伐珠单抗浓度越高;但基线总剂量与血浆VEGF浓度百分比变化无关。作者结论认为低至0.002 mg的贝伐珠单抗仍与多数患儿2周和4周血浆VEGF水平降低相关,需进一步研究低剂量贝伐珠单抗对神经发育和视网膜结构的长期影响。
要点
- 基线总剂量越高,2周(ρ=0.53)和4周(ρ=0.44)血浆贝伐珠单抗浓度越高。
- 2周时66例中40例(61%)、4周时61例中31例(51%)血浆VEGF较治疗前降低50%及以上。
- 基线总剂量与2周(ρ=-0.04)或4周(ρ=-0.17)血浆VEGF百分比变化无关联。
核心结论
- 作者结论认为,低至0.002 mg的贝伐珠单抗剂量在多数患儿中与眼内注射后2周和4周血浆VEGF水平降低相关。
- 作者结论认为,基线给予的贝伐珠单抗总剂量与血浆VEGF从注射前至2周或4周的降低幅度之间未观察到关联。
- 作者指出需要额外研究来评估低剂量贝伐珠单抗对神经发育和视网膜结构的长期影响。
研究设计与样本
- 这是一项1期剂量递减病例系列研究,于2015年5月21日至2019年5月7日在美国10家眼科机构医院开展。
- 研究纳入83例1型早产儿视网膜病变患儿(单眼或双眼),此前未接受过ROP治疗,平均(SD)年龄25(2)周,男孩48例(58%)。
- 研究眼接受单次贝伐珠单抗注射,剂量为0.250 mg、0.125 mg、0.063 mg、0.031 mg、0.016 mg、0.008 mg、0.004 mg或0.002 mg;对侧眼需要治疗时给予高一个梯度的剂量。
- 基线总剂量定义为初始研究眼注射后3天内每只眼给药剂量之和;注射后2周和4周采集血样。
- 数据分析时间为2017年4月至2021年8月。
主要发现
- 基线给予较高剂量贝伐珠单抗与2周时较高的血浆贝伐珠单抗浓度相关(ρ=0.53;95%CI 0.31-0.70)。
- 基线给予较高剂量贝伐珠单抗与4周时较高的血浆贝伐珠单抗浓度相关(ρ=0.44;95%CI 0.18-0.64)。
- 2周时66例中40例(61%)血浆VEGF浓度较治疗前降低50%及以上。
- 4周时61例中31例(51%)血浆VEGF浓度较治疗前降低50%及以上。
- 基线贝伐珠单抗总剂量与2周时血浆VEGF浓度百分比变化无关联(ρ=-0.04;95%CI -0.28至0.20),与4周时也无关联(ρ=-0.17;95%CI -0.41至0.08)。
临床怎么用
- 作者结论认为,低至0.002 mg的贝伐珠单抗剂量在多数患儿中与2周和4周血浆VEGF水平降低相关。
- 作者结论认为,基线贝伐珠单抗总剂量与血浆VEGF从注射前至2周或4周的降低幅度之间未观察到关联。
- 作者指出需要额外研究来评估低剂量贝伐珠单抗对神经发育和视网膜结构的长期影响。
局限性
- 作者指出需要额外研究来评估低剂量贝伐珠单抗对神经发育和视网膜结构的长期影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Intravitreal bevacizumab effectively treats severe retinopathy of prematurity (ROP), but it enters the bloodstream and may reduce serum vascular endothelial growth factor (VEGF), potentially causing detrimental effects on developing organs in the premature infant. OBJECTIVE: To evaluate the association of intravitreal bevacizumab with plasma bevacizumab and VEGF concentrations at 2 and 4 weeks after predefined, de-escalating doses of intravitreal bevacizumab were administered to infants with severe ROP. DESIGN, SETTING, AND PARTICIPANTS: This phase 1 dose de-escalation case series study was conducted at 10 US hospitals of ophthalmology institutions from May 21, 2015, to May 7, 2019. Blood samples were collected 2 and 4 weeks after intravitreal bevacizumab injection. Participants included 83 premature infants with type 1 ROP in 1 or both eyes and no previous ROP treatment. Data were analyzed from April 2017 to August 2021. INTERVENTIONS: Study eyes received a single bevacizumab injection of 0.250 mg, 0.125 mg, 0.063 mg, 0.031 mg, 0.016 mg, 0.008 mg, 0.004 mg, or 0.002 mg. When the fellow eye required treatment, one dose higher was administered. Total dose administered at baseline was defined as the sum of doses given to each eye within 3 days of initial study-eye injection. MAIN OUTCOMES AND MEASURES: Plasma bevacizumab concentration at 2 and 4 weeks after injection and the percentage change in plasma VEGF concentrations from pretreatment levels. RESULTS: A total of 83 infants (mean [SD] age, 25 [2] weeks; 48 boys [58%]) were included in this study. Higher doses of bevacizumab administered at baseline were associated with higher plasma bevacizumab concentrations at 2 weeks (ρ, 0.53; 95% CI, 0.31-0.70) and 4 weeks (ρ, 0.44; 95% CI, 0.18-0.64). Plasma VEGF concentrations decreased by 50% or more from pretreatment levels in 40 of 66 infants (61%) at 2 weeks and 31 of 61 infants (51%) at 4 weeks, but no association was observed between the total dose of bevacizumab administered at baseline and percentage change in plasma VEGF concentrations 2 weeks (ρ, -0.04; 95% CI, -0.28 to 0.20) or 4 weeks (ρ, -0.17; 95% CI, -0.41 to 0.08) after injection. CONCLUSIONS AND RELEVANCE: Results of this phase 1 dose de-escalation case series study revealed that bevacizumab doses as low as 0.002 mg were associated with reduced plasma VEGF levels for most infants at 2 and 4 weeks after intravitreal administration; however, no association was observed between total bevacizumab dose administered and reductions in plasma VEGF levels from preinjection to 2 weeks or 4 weeks. Additional studies are needed to evaluate the long-term effects of low-dose bevacizumab on neurodevelopment and retinal structure.
引用
- Hartnett ME, Wallace DK, Dean TW, et al. Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants. JAMA Ophthalmol. 2022. PMID: 35446359. doi:10.1001/jamaophthalmol.2022.0030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。